Impact of Prostatic Artery Embolization in Patients with Enlarged True Middle Lobes

Willi Zhou¹, Peter Bischoff¹, Herbert Hanitzsch², Matthias Schmidt², Andreas Schäfer¹, Ayoub El-Mansouri¹, Attila Kovács¹,*

¹Clinic for diagnostic and Interventional Radiology and Neuroradiology, MediClin Robert Janker Klinik, 53129 Bonn, Germany
²Department for Urology, Urology Centre Friedensplatz, 53111 Bonn, Germany
*Correspondence: attila.kovacs@mediclin.de (Attila Kovács)
Submitted: 18 January 2022 Revised: 18 March 2022 Accepted: 25 March 2022 Published: 17 November 2022

Abstract

Background: Prostatic artery embolization (PAE) is an emerging minimal-invasive therapy of benign prostatic hyperplasia (BPH), able to reduce the prostatic volume (PVol) and the IPP. The presence of a true middle lobe (TML) is associated with bladder outlet obstruction (BOO), causing lower urinary tract symptoms (LUTS). In this study we investigate the effect of PAE in TML improvement in patients with LUTS. Methods: A retrospective analysis was done of 47 men treated with PAE from April 2015 to September 2021. The volume of the TML, IPP, and PUA were measured on MRI prior and 2 months after PAE. Successful devascularization of the TML was evaluated by contrast-enhanced MRI (ceMRI) 48 hours after therapy. Results: The TML was successfully embolised technically in 72%. After two months, the total volume of the prostate (PVol) was reduced by 25.8 ± 13.3% (from 72.1 ± 39.8 cc to 52.5 ± 27.9 cc; p < 0.000). Following a technically successful PAE of the TML, the TMLVol decreased by 32.1 ± 21.5% (from 10.6 ± 16.1 cc to 7.2 ± 13.1 cc; p < 0.000), and the IPP was reduced by 29.3 ± 15.5% (from 16.3 ± 7.4 mm to 11.9 ± 6.6 mm; p < 0.000). In contrast, after a technically incomplete devascularisation of the TML the TMLVol decreased by only 7.2 ± 17.7% (from 8.4 ± 9.3 cc to 7.5 ± 8.9 cc; p = 0.089), and the IPP was reduced by only 10.9 ± 8.8% (from 16.4 ± 7.3 mm to 14.6 ± 6.7 mm; p = 0.003). The current of the PUA after a successful and after an incomplete embolization of the TML was comparable with 11.6 ± 7.6 and 12.2 ± 9.4, respectively (in both p < 0.001). Conclusions: Our study firstly shows that PAE is able to reduce TML volume. Furthermore, PAE is able to reduce the IPP even if caused by a TML.

Keywords: benign prostatic hyperplasia; lower urinary tract symptoms; prostatic artery embolisation; minimal-invasive therapy; true middle lobe

1. Introduction

The pathophysiology of male lower urinary tract symptoms (LUTS) is complex and multifactorial. A common cause of LUTS is benign prostatic hyperplasia (BPH). A key morphological parameter of the enlarged prostate that influence bladder outlet obstruction (BOO) is the intravesical prostatic protrusion (IPP) [1,2]. The IPP is defined as the protrusion of the prostate into the lumen of the bladder. IPP thus refers to the morphological disorder without specifying which anatomical structure it is formed by. The IPP may be caused by a TML and/or lateral lobes (Fig. 1A and B) [3]. Prostatic artery embolization (PAE) is an emerging minimal-invasive therapy of BPH, able to reduce the prostatic volume (PV) and the IPP [2,4–7]. True Middle Lobes (TML) are technically difficult to embolize (Fig. 1D) and are considered to be a relative contraindication to PAE [8]. To the best of our knowledge, there is currently no publication that has investigated the effect of PAE on TML improvement in patients with LUTS. Only patients in whom the IPP was formed only by the TML were included in this study.

2. Material and Methods

A retrospective analysis was done of 47 men with TML treated with PAE from April 2015 to September 2021. The IPP, the prostatic urethral angle (PUA), and the volume of the TML (TMLVol), were measured on MRI prior and 2 months after PAE. The IPP was measured on the mid sagittal plane in T2-weighted MR-images of the prostate as the shortest perpendicular distance between the protruded end of the prostate and the bladder base on the bladder neck in the sagittal plane. The PUA was measured as the angle between the prostatic urethra and the membranous urethra in the midsagittal plane also at MRI. The volume of the TML was measured in the multiplanar MRI using the volume formula $a \times b \times c/2$; where $a$, $b$, and $c$ are the diameters in all three spatial directions. During embolisation of the TML, we targeted the TML-supplying artery shown in Fig. 1. In order to ensure that the target vessel supplies the entire TML, we performed a pre-therapeutic (i.e., before embolisation) simulation using a capillary cone beam CT (cCBCT) in all cases. The technical success of PAE of the TML, defined as a complete devascularization of the TML was evaluated on contrast-enhanced MRI (ceMRI) 48 hours after therapy. Patients with urologic tumors, neurogenic
Intravesical prostatic protrusion (IPP) caused by the lateral lobes of the prostate or by the middle lobe. (A) T2-weighted MRI of the prostate, with coronal angulation. The IPP relocates the urinary bladder outlet. The MRI clearly shows that the IPP is formed by the left lateral lobe in this case (outlined in green). (B) T2-weighted MRI of the prostate, coronal angulation. The urinary bladder outlet is also displaced by the IPP. The MRI clearly shows that the IPP is formed by the middle lobe in this case (outlined in green). (C) Angiography image of the prostate in the context of PAE. If the IPP is formed by the lateral lobe, the IPP is also supplied by the lateral lobe artery (red arrow). (D) Angiography image of the prostate in the context of PAE. If the IPP is formed by the middle lobe, the IPP is supplied by its own artery, which usually runs along the prostatic urethra from the apex to the base (red arrow).

bladder, urinary tract infection, bladder stones, which could affect voiding, were excluded. PAE was carried out with calibrated spheric embolic agents with a diameter of 300–500 µm (Merit Embospheres®). SPSS ver. 13.0 (SPSS Inc., Chicago, IL, USA) was used for statistical analysis. p-values of <0.05 were considered statistically significant.

3. Results

The mean age was 66.4 ± 9.6 years. According to the ceMRI 48 hours after PAE, the TML was successfully embolised technically in 72% (34 of 47 patients). After two months, the total volume of the prostate (PVol) was reduced by an average of 19.5 ± 19.6 cc, from 72.1 ± 39.8 cc to 52.5 ± 27.9 cc (p < 0.000). This corresponds to 25.8 ± 13.3% volume reduction (Fig. 2).

Following a technically successful PAE of the TML, the TMLVol decreased by 3.3 ± 4.3 cc, from 10.6 ± 16.1 cc to 7.2 ± 13.1 cc (p < 0.000). This corresponds to 32.1 ± 21.5% volume reduction. In contrast, the TMLVol decreased after a technically incomplete devascularisation of the TML by 0.8 ± 1.6 cc from 8.4 ± 9.3 cc to 7.5 ± 8.9 cc (p < 0.09). This corresponds to 7.2 ± 17.7% volume reduction (Figs. 3 and 4). A similar result can be observed for the IPP. Following a technically successful PAE of the
Both the volume reduction of the TML and the height of the IPP are reduced more significantly after successful devascularisation of the TML than after incomplete devascularisation.

TML, the IPP was reduced by $4.4 \pm 2.9$ mm, from $16.3 \pm 7.4$ mm to $11.9 \pm 6.6$ mm ($p < 0.000$). This corresponds to a reduction by $29.3 \pm 15.5\%$. In contrast, after incomplete devascularization of the TML the IPP was reduced by $1.8 \pm 1.9$ mm, from $16.4 \pm 7.3$ mm to $14.6 \pm 6.7$ mm ($p < 0.004$). This corresponds to a reduction by $10.9 \pm 8.8\%$ (Figs. 4 and 5).

The curvature of the PUA after a successful and after an incomplete embolization of the TML was comparable with $11.6 \pm 7.6$ ($p < 0.000$) and $12.2 \pm 9.4$ ($p < 0.001$), respectively.

In 8.5% (4/47) of patients, a mild postembolisation syndrome was seen in the first two days after PAE. Postembolisation syndrome (PES) summarise temporary dysfunctional disorders, that may occur in the first days after treatment. These temporary complaints (urodynia, urine discoloration, and spasms) can usually be effectively controlled by non-steroidal anti-inflammatory drugs (NSAIDs).
Accordingly, to the TMLVol (Fig. 3), considerable IPP reduction was achieved after successful embolization of the TML: In 31 out of 34 cases (91.2%) IPP decreased significantly after successful TML devascularization. By contrast, without complete devascularization of the TML, IPP stayed indifferent or showed only a slight reduction.

such as ibuprofen p.o., usually combined with a proton pump inhibitor. In case of spasms a combination with spasmyloyis is suggested. Additional analgetics are generally not required.

The median dose area product (DAP) was 75.35 Gycm², which corresponds to an effective dose (ED) of 19 mSv.

4. Discussion

We here present the first single centre retrospective study proving the positive effect of PAE not only on the reduction of PV, IPP and PUA, but also on the volume of TML (Fig. 6). Our results suggest that IPP and TML are two closely physiologically linked parameters. Further, the TML, has only a subordinate role on PUA.

While BPH represents a histological diagnosis, LUTS comprises a symptom complex. BPH is a common cause of LUTS, predominantly in older men [8]. In fact, a variety of conditions can lead to LUTS, so that only about a quarter to half of patients with proven BPH also have LUTS, and conversely, of men with LUTS, only about 50% have urodynamically proven BOO. Although the prevalence is high, many questions about the pathogenesis of LUTS remain rather incompletely answered [9,10].

Clinically, the diagnosis of BPH and BOO is usually made based on PV >40 mL, a maximum flow rate (Qmax) <10 mL/s, in combination with a high IPSS [9]. Many clinical studies have demonstrated that LUTS have poor diagnostic specificity for BOO, moreover the correlation between PV and LUTS severity is weak [7,10].

It is well studied and known that the effect of PAE goes beyond volume reduction alone [11]. The reason lies in the variety of therapeutic effects of PAE and their synergistic effects: (1) shrinkage of the enlarged prostate gland as a result of ischemic infarction, (2) relaxation of the increased prostatic smooth muscle tone by reducing the prostate stroma and additionally α-adrenergic denervation, (3) the softening effect of nitric oxide pathway, (4) blockage of androgen circulation into the prostate, and (5) ischemia-induced apoptosis [11].

Our study is one of the first to evaluate changes in TML as well as in IPP following PAE. The IPS-score correlate only partially with prostate enlargement, BOO and LUTS [12]. Further, there is no fixed correlation between PVol, and BOO [13]. Eckhardt MD et al. [14] demonstrated in a study from 2001, that patients with LUTS primarily suffer from storage symptoms, particularly urge incontinence and nocturia. The particular burden of irritative storage symptoms has been confirmed by follow-up studies [15,16]. Therefore, as is so often the case in the relevant literature, it is only of limited use to take the total volume of the prostate as a reference value for the success of the therapy and as a morphological correlate for clinical improvement.

IPP is of increasing interest in the context of PAE. The prevalence of IPP is reported to be 27% in Caucasians aged 41–88 years. IPP and BOO index correlate positively with each other, whereas drug therapy strategies and significant IPP correlate negatively. Analogous to IPP, TML must also be scientifically evaluated, especially since the enlarged middle lobe originating from the periurethral zone often leads to mechanical bladder outlet obstruction. In addition, hyperplasia of the lateral lobe originating from the transition zone may also be involved in IPP. Pathophysiologically, IPP produces a type of “ball valve” obstruction that disrupts the funnel effect of the bladder neck and leads to dyskinesias of the bladder muscles during voiding [17].

Downsizing of the middle lobe resulted in a significant decrease in the mean IPP index three months after PAE in a prospective study of 18 patients. This in turn correlated with the IPS score and it was concluded that approximately 40% of the change in clinical relief of IPSS could be explained by a decrease in the IPP index [18]. Another analysis stratifying IPP patients by thickness-to-height ratio (T/H ratio), using a cut-off value of 1.3, found that IPP with a T/H ratio ≤1.3 correlated with suboptimal IPSS at 12 months (p = 0.025) and suboptimal QoL at 6 months (p = 0.025) and 12 months (p = 0.008) [19]. In addition, complications such as de novo AUR seemed to occur more frequently in patients with IPP. However, even with successful devascularisation of the IPP, BOO may worsen and AUR may develop due to the valve effect. This highlights the need for further in-

Fig. 5. Course of the intravesical prostatic protrusion (IPP) two month after the prostatic artery embolization (PAE).
Fig. 6. 59-year-old patient with pronounced LUTS (IPSS 27), severely impaired quality of life and without impairment of erectile function (IIEF 24). The patient explicitly desired ejaculation-preserving therapy. (A) Pretherapeutic diagnostic MRI (sag T2w) with the pronounced IPP. (B) Coronal angulated ceMRI 48 hours post PAE clearly shows complete devascularisation of the TML. (C) Follow-up MRI 2 months post PAE shows a marked reduction in IPP with persistent signs of devascularisation.

Fig. 7. (A) PAE is a procedure that helps achieve the goal of preserving ejaculation, quality of life and continence. (B) Post-PAE MRI shows devascularised TML. (C) Follow-up MRI shows a reduction in IPP.

The patient explicitly desired ejaculation-preserving therapy. (A) Pretherapeutic diagnostic MRI (sag T2w) with the pronounced IPP. (B) Coronal angulated ceMRI 48 hours post PAE clearly shows complete devascularisation of the TML. (C) Follow-up MRI 2 months post PAE shows a marked reduction in IPP with persistent signs of devascularisation.

Fig. 8. (A) PAE is a minimally invasive treatment option for BPH. (B) Post-PAE MRI shows devascularised TML. (C) Follow-up MRI shows a reduction in IPP.
5. Conclusions

The IPP, regardless of whether it is formed by the lateral lobe or the middle lobe, should be considered as an important clinical factor in male LUTS management. PAE is currently considered a potential link between the exhausted medical management and more or less radical resection-based interventions. Our study found that PAE is able to reduce the IPP even if it is formed exclusively by a TML. Particularly in view of the fact that patients with larger IPPs respond less well to different drug therapies, minimally invasive therapy options must be researched for the targeted therapy of IPP and, equivalently, TML.

Author Contributions

WZ—constitution of scripture; PB—execution of the interventions; HH—urological preselection and aftercare; MS—urological preselection and aftercare; AS—diagnostic imaging; AEM—data analysis; AK—supervision and corresponding author.

Ethics Approval and Consent to Participate

The participants were informed about the study procedures and a written informed consent was signed. The study was conducted in accordance with the Declaration of Helsinki, and the protocol was approved by the local ethics committee of Universitätsklinikum Schleswig-Holstein, Campus Lübeck (approval number: 17 – 237A, August 2017).

Acknowledgment

Not applicable.

Funding

This research received no external funding.

Conflict of Interest

The authors declare no conflict of interest.

References